Electrogenetic cellular insulin release for real-time glycemic control in type 1 diabetic mice.
Krzysztof KrawczykShuai XuePeter BuchmannGhislaine Charpin-El-HamriPratik SaxenaMarie-Didiée HussherrJiawei ShaoHaifeng YeMingqi XieMartin FusseneggerPublished in: Science (New York, N.Y.) (2020)
Sophisticated devices for remote-controlled medical interventions require an electrogenetic interface that uses digital electronic input to directly program cellular behavior. We present a cofactor-free bioelectronic interface that directly links wireless-powered electrical stimulation of human cells to either synthetic promoter-driven transgene expression or rapid secretion of constitutively expressed protein therapeutics from vesicular stores. Electrogenetic control was achieved by coupling ectopic expression of the L-type voltage-gated channel CaV1.2 and the inwardly rectifying potassium channel Kir2.1 to the desired output through endogenous calcium signaling. Focusing on type 1 diabetes, we engineered electrosensitive human β cells (Electroβ cells). Wireless electrical stimulation of Electroβ cells inside a custom-built bioelectronic device provided real-time control of vesicular insulin release; insulin levels peaked within 10 minutes. When subcutaneously implanted, this electrotriggered vesicular release system restored normoglycemia in type 1 diabetic mice.
Keyphrases
- glycemic control
- type diabetes
- induced apoptosis
- blood glucose
- poor prognosis
- cell cycle arrest
- insulin resistance
- spinal cord injury
- weight loss
- cardiovascular disease
- healthcare
- binding protein
- gene expression
- small molecule
- physical activity
- high speed
- cell death
- transcription factor
- cell proliferation
- long non coding rna
- room temperature